Supplemental materials for: Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone
This work has been approved by Institutional Review Boards in Sierra Leone (Sierra Leone Ethics and Scientific Review Committee, SLESRC) and the United States (Harvard Committee on the Use of Human Subjects, CUHS, the CDC’s Human Research Protection Office, HSPO). As part of the EVD outbreak response and surveillance efforts, residual human clinical samples were collected under a waiver of consent granted by SLESRC and CUHS, and the EBOV sequencing work has received non-human subjects research determination by CUHS and HSPO. The Sierra Leone Ministry of Health and Sanitation approved shipment of non-infectious, inactivated samples collected from EVD patients to Broad Institute and Harvard University for viral sequencing. The EBOV-related research and laboratory safety protocols are registered with the Committee of Microbiological Safety (COMS) at Harvard University, and the viral sequencing work is registered with the Institutional Biosafety Committee at Broad Institute. All work with infectious or potentially infectious material was performed at the CDC Viral Special Pathogens Branch in Atlanta, GA, under biosafety level 4 (BSL-4) conditions. Our work was not deemed to be dual-use research of concern.